Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 October 2022 | Story NONSINDISO QWABE | Photo Rio Button
The Lowveld serotine bat, named Neoromicia hlandzeni
The Lowveld serotine bat, named Neoromicia hlandzeni.

Biological expeditions to the unexplored central highlands of Angola between 2016 and 2019 led to the discovery of a new tiny, white-thumbed bat species from Eswatini by Prof Peter John Taylor from the UFS Department of Zoology and Entomology and the Afromontane Research Unit (ARU), together with colleagues from the University of Eswatini (UNESWA) and other collaborators.

The bat species, named Neoromicia hlandzeni or the Lowveld serotine bat – after the Lowveld of Eswatini (eHlandzeni) – is the first new animal species to be discovered in Eswatini and given a siSwati name. The Lowveld serotine bat is tiny at four grams, has a distinctive white thumb pad, and occurs in Eswatini, South Africa, Zimbabwe, and Mozambique.

Bats make up a quarter of all mammalian biodiversity. With modern technology and the exploration of previously inaccessible regions of Africa, the rate of discovery of both animal and plant species is accelerating.

According to Prof Taylor, the Lowveld serotine bat is a new species to science. The specimen from which the species was named was collected in the lowlands of Eswatini in 2005. “Later collections of bats from the highlands of Angola, undertaken by myself and students, revealed the fact that the highland and lowland forms were actually different species. Since there was already a name for the highland bat, we needed to find a new name for the lowland bat from Eswatini and South Africa, hence it is called the Lowveld serotine bat,” he said.

The importance of integrative taxonomy, local collaboration, and biodiversity surveys

Prof Taylor is a research fellow of the National Geographic Okavango Wilderness Project, and the bat discovery took place during expeditions under the patronage of the Angolan government, the Wild Bird Trust, and the National Geographic Okavango Wilderness Project. He said the aim of the expedition was to explore the plants and animals of a wilderness area (the source of the Okavango) that had not been explored before.

The discovery also led to their paper being published in the scientific journal, the Zoological Journal of the Linnean Society, this month. 

The publication, titled Integrative taxonomic analysis of new collections from the central Angolan highlands resolves the taxonomy of African pipistrelloid bats on a continental scale, showcases the importance of integrative taxonomy, local collaboration, and biodiversity surveys, as the description of this exciting new species would not have been possible without comparative genetic and morphological material from new collections in the poorly sampled central highlands of Angola. 
Prof Peter Taylor with his students, Veli Mdluli and Alexandra Howard
Prof Peter Taylor with his students, Veli Mdluli and Alexandra Howard, working on bat research. Howard was one of the co-authors of the paper. (Photo: Supplied)

Afromontane regions as hotspots of bat speciation, diversity, and micro-endemism

Although Prof Taylor is the first author to describe this new species, the work was done with a multidisciplinary team of colleagues, students, and collaborators from the UFS, UNESWA, the University of Pretoria, the University of Venda, and Stellenbosch University, as well as the Durban Natural Science Museum and the Ditsong National Museum of Natural History, with support from the Angolan government, the Wild Bird Trust, and the National Geographic Okavango Wilderness Project. 
“Describing a new species is an arduous task that can take years from discovery to publication. All the enormous collective efforts have shown the importance of collaborative biodiversity exploration using old and modern technologies, as well as the African ownership of this discovery,” Prof Taylor said.

Three of Prof Taylor's previous and current PhD students – all of them South African women – were part of this discovery process and are co-authors of the paper. All 14 co-authors in the team are African. Prof Taylor said the discovery adds a new species to the total bat list of 125 species for Southern Africa – at number 126.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept